{
Sartorius Stedim Biotech S.A.

Companies

}
001122334455554433221100
001122334455554433221100

health sector shows resilience amid potential us tariffs on pharmaceuticals

In Paris, the health sector shows resilience as Eurofins Scientific and Sanofi rise amid a downbeat CAC 40, unaffected by upcoming U.S. tariffs set for April 2025. However, UBS warns that the sector may still face challenges, including potential additional tariffs from Trump targeting pharmaceuticals. Sartorius Stedim Biotech sees a decline, reflecting concerns over U.S. sales exposure and tariff implications.
bourse.fortuneo.fr
Euro MedinCell S.A. Sartorius Stedim Biotech S.A. Sanofi Eurofins Scientific S.E. A Ipsen S.A. FRA USA Charles Weston Donald Trump Show more
Finance & Economy, Market Report
11:33 03.04.2025

ubs rates sartorius stedim biotech as neutral amid investment risks

UBS has rated Sartorius Stedim Biotech as 'Neutral'. The information provided is for informational purposes only and does not constitute a recommendation to buy or sell securities. Investing carries risks, including the potential loss of capital, and expert investment advice is recommended.
wallstreetONLINE
Sartorius Stedim Biotech S.A.
Finance & Economy, Market Report
08:34 29.01.2025

ubs raises price target for sartorius stedim biotech while maintaining neutral rating

UBS has increased its price target for Sartorius Stedim Biotech from 222 to 244 euros following strong preliminary quarterly results, while maintaining a "Neutral" rating. Analyst Matthew Weston noted signs of growth and a conservative outlook for 2025 after previous target reductions. Estimates for 2025 to 2029 have also been raised.
boerse.de
Euro Sartorius Stedim Biotech S.A. FRA CHE Matthew Weston
Finance & Economy, Market Report
08:34 29.01.2025

ubs raises target price for sartorius stedim biotech to 244 euros

UBS has increased its target price for Sartorius Stedim Biotech from 222 to 244 euros following strong preliminary quarterly results, while maintaining a "Neutral" rating. Analyst Matthew Weston noted signs of a return to growth, although management remains conservative in its 2025 outlook after previous target reductions. Estimates for 2025 to 2029 have been raised accordingly.
de.marketscreener.com
Euro Sartorius Stedim Biotech S.A. FRA CHE Matthew Weston
Finance & Economy, Market Report
07:34 29.01.2025

ubs raises target price for sartorius stedim biotech to 244 euros

UBS has increased its target price for Sartorius Stedim Biotech from 222 to 244 euros following strong preliminary quarterly results, while maintaining a "Neutral" rating. Analyst Matthew Weston noted signs of a return to growth, although management remains conservative about the 2025 outlook. Estimates for 2025 to 2029 have been raised accordingly.
aktiencheck.de
Euro Sartorius Stedim Biotech S.A. DEU FRA Matthew Weston
Finance & Economy, Market Report
07:34 29.01.2025

UBS maintains neutral rating for Sartorius Stedim with target at 222 euros

UBS has maintained a 'Neutral' rating for Sartorius Stedim Biotech, setting a price target of 222 euros ahead of the upcoming fourth quarter results. Analyst Matthew Weston anticipates mixed outcomes, with ongoing recovery in the Bioprocess Consumables division, but expects management to lower medium-term targets significantly during the annual report.
boerse.de
Euro Sartorius Stedim Biotech S.A. DEU CHE FRA Matthew Weston Thomas Müller Show more
Finance & Economy, Market Report
14:04 24.01.2025

ubs assigns neutral rating to sartorius stedim biotech

UBS has rated Sartorius Stedim Biotech as 'Neutral'. The information provided is for informational purposes only and does not constitute a recommendation to buy or sell securities. Investing carries risks, including the potential loss of capital, and expert investment advice is recommended.
wallstreetONLINE
Sartorius Stedim Biotech S.A.
Finance & Economy, Market Report
14:04 24.01.2025

ubs maintains neutral rating for sartorius stedim with target price of 222 euros

UBS has maintained a 'Neutral' rating for Sartorius Stedim Biotech, setting a target price of 222 euros ahead of the upcoming fourth quarter results. Analyst Matthew Weston anticipates mixed outcomes, with ongoing recovery in the Bioprocess Consumables division, but expects management to lower medium-term targets significantly during the annual report.
MarketScreener
Euro Sartorius Stedim Biotech S.A. CHE Matthew Weston
Finance & Economy, Market Report
13:51 24.01.2025

ubs maintains neutral rating for sartorius stedim with target price of 222 euros

UBS has maintained a 'Neutral' rating for Sartorius Stedim Biotech, setting a target price of 222 euros ahead of the upcoming fourth quarter results. Analyst Matthew Weston anticipates mixed outcomes, with ongoing recovery in the Bioprocess Consumables division, but expects management to lower medium-term targets significantly during the annual report. As of January 24, the stock was trading at 208.70 euros, reflecting a 0.53% increase.
aktiencheck.de
Euro Sartorius Stedim Biotech S.A. CHE Matthew Weston
Finance & Economy, Market Report
13:04 24.01.2025

ubs raises price target for sartorius stedim biotech shares amid positive outlook

Sartorius Stedim Biotech shares fell 1.01% to EUR 198.08 on October 22, 2024, despite UBS raising its price target from EUR 194 to EUR 215 after strong quarterly results. Over the past year, shares have increased by 9.62%, although they remain 41.89% below their 52-week high, presenting a potential buying opportunity for investors.
aktiencheck.de
Euro Sartorius Stedim Biotech S.A. CHE DEU UBS
TradFi, Market Report
00:14 23.10.2024
Trending
Subcategory
Startups & Entrepreneurship Industry Trends Corporate News Private Equity Deals Retail and Consumer Goods Supply Chain Management Global Trade Developments CEO Changes Government Economic Policies Corporate Social Responsibility Industry Mergers & Acquisitions Workplace Trends Energy Sector Developments Venture Capital Investments Fintech Startups Finance Mergers & Acquisitions AI Innovations Market Analysis and Predictions Intellectual Property Laws Central Bank Actions
Countries:
IND USA CHN SAU ARE SGP JPN QAT EGY MYS IDN GBR KOR BRA HKG VNM TWN DEU FRA IRL
Companies:
Apple Inc. NVIDIA Corporation Google Inc. Amazon.com, Inc. Tesla, Inc. Salesforce, Inc. Garuda Aerospace Ltd. Huawei Technologies CO. Ltd. Bharti Airtel Ltd. XPeng Inc. Microsoft Corporation Venturewave Capital NO.1 Ltd. Semler Scientific, Inc. TENCENT Wipro Ltd OpenAI ERC USD Orange S.A. IDBI Bank Limited Standard Chartered Bank LENOVO GROUP
Currencies:
United States Dollar Indian Rupee Chinese Yuan Euro Saudi Riyal Japanese Yen Malaysian Ringgit British Pound Sterling Mexican Peso Brazilian Real New Taiwan Dollar Bahraini Dinar Qatari Riyal Pakistani Rupee Kuwaiti Dinar Vietnamese Đồng South Korean Won Algerian Dinar
People:
Donald Trump Mark Zuckerberg Bisrat Degefa He Xiaopeng Abdel Fattah El-Sisi Anmol Singh Jaggi Puneet Singh Jaggi Sari Sabban David Watkins Simon Moon Anas Algahtani Matt Jones Ayman Hamdan Elon Musk Allen Law Xi Jinping Anwar Hussain Sultan Ibrahim ibni Sultan Iskandar Prashant Joshi Albinder Dhindsa

Machinary offers a groundbreaking, modular, and customizable solution that provides advanced financial news and statistical analysis. Our platform goes beyond traditional quantitative analysis, offering users a comprehensive understanding of real-time market dynamics, event detection, and risk analysis.

Links

Address

Newsletter

© 2025 by Machinary.com - Version: 1.0.0.0. All rights reserved

Layout

Color mode

Theme mode

Layout settings

Save settings
Reset settings
Seems like the connection with the server has been lost. It can be due to poor or broken network. Please hang on while we're trying to reconnect...
Oh snap! Failed to reconnect with the server. This is typically caused by a longer network outage, or if the server has been taken down. You can try to reconnect, but if that does not work, you need to reload the page.
Oh man! The server rejected the attempt to reconnect. The only option now is to reload the page, but be prepared that it won't work, since this is typically caused by a failure on the server.